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Objectives In this study, our goal was to determine if human resistin plays a role in regulating the uptake of atherogenic
low-density lipoproteins in human hepatocytes.
Background Serum levels of resistin, an adipose tissue–derived adipokine, are increased in human obesity and are positively
correlated with atherosclerotic cardiovascular diseases. However, the function of resistin in humans is enigmatic.
Methods Human hepatocytes (HepG2 and primary) were treated (24 h) with the following: 1) purified human resistin at
various concentrations, with and without lovastatin; and 2) obese human serum with elevated resistin levels or
serum from which resistin was removed via antibody-immunoprecipitation. The effect of the treatments on cellu-
lar low-density lipoprotein receptor (LDLR) and proprotein convertase subtilisin/kexin type 9 (PCSK9) messenger
ribonucleic acid and protein levels were determined by using real-time polymerase chain reaction and Western
blotting, respectively.
Results Resistin, at physiological levels observed in human obesity, down-regulated hepatocyte LDLR expression
substantially (by 40%). A key mechanism by which human resistin inhibited LDLR levels was by increased
cellular expression of the recently identified protease, PCSK9, which enhances intracellular LDLR lysosomal
degradation. The quantitatively important role of human resistin in LDLR expression was demonstrated by
antibody-immunoprecipitation removal of resistin in human serum, which decreased serum stimulation of
hepatocyte LDLRs markedly (by 80%). Furthermore, resistin diminished statin-mediated up-regulation of the
LDLR by 60%, implicating resistin in the relative ineffectiveness of statins in selective target populations.
Conclusions These results reveal for the first time that resistin is a highly attractive therapeutic target in ameliorating elevated
serum low-density lipoprotein and, thereby, atherosclerotic cardiovascular diseases in obese humans. (J Am Coll
Cardiol 2012;59:1697–705) © 2012 by the American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.11.064Obesity is a growing global epidemic, with more than 400
million obese adults worldwide (1). The consequences of
obesity are dire, as obesity is a major cause of metabolic
syndrome, leading to atherosclerotic cardiovascular diseases
(ASCVD), with high associated morbidity and mortality
rates (2,3). One of the earliest and most prevalent metabolic
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elevated serum levels of atherogenic apolipoprotein B–
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low-density lipoprotein (LDL).
Elevated numbers of LDL parti-
cles comprise a major component
of the characteristic and common
dyslipidemia in human obesity,
known as the lipid triad or
atherogenic dyslipidemia, which
also includes high serum triglyc-
erides and low serum levels of
high-density lipoprotein choles-
terol (5,6).
The lipid triad is most highly
prevalent in obese individuals with
central or visceral abdominal obe-
sity, the most metabolically ad-
verse type of obesity, which engen-
ders the highest risk of ASCVD
(5,6). The lipid triad overall greatly
raises the risk for myocardial in-
farction, coronary heart disease,
and ASCVD in general.
The component of the triad
involving LDL delineates that
although LDL particle numbers are characteristically in-
creased in obesity, reflected by elevated serum apolipopro-
tein B levels (7), the LDL particles themselves are typically
small and dense and thus contain lower lipid levels.
Thereby, serum LDL cholesterol levels are not always
elevated in obesity, although LDL cholesterol is usually at
least moderately elevated, and in many cases, highly elevated
in obesity (6,8,9). Nonetheless, elevated numbers of LDL
particles, or elevated apolipoprotein B, are strong ASCVD risk
factors and play a major role in the initiation and development
of atherosclerosis (6,9,10), as they result in increased uptake of
atherosclerotic LDL particles into the vascular wall, where they
are retained (7). In fact, elevated circulating LDL is both
ecessary and sufficient to promote ASCVD (11).
However, our understanding of the mechanisms respon-
ible for elevated LDL in obesity is only rudimentary.
verproduction of apolipoprotein B–containing particles,
ncluding LDL, by the liver can partially explain the
levation in serum LDL levels in obesity (12). However, in
ost metabolic states, regulation of circulating LDL levels
s controlled in large part by the rate of liver uptake and
learance of LDL particles by hepatocyte cell surface low-
ensity lipoprotein receptors (LDLRs) (12–14). Indeed,
ecreased expression of LDLRs and decreased catabolism,
ptake, and clearance of LDL particles have been shown to
e major contributors of elevated serum LDL in obesity,
specially visceral obesity (12,15,16). Despite the central
ole of the LDLR in regulating circulating LDL concen-
rations, few physiological factors have been identified that
irectly affect hepatic LDLR levels.
We identify here a major role for resistin, an adipose
Abbreviations
and Acronyms
ASCVD  atherosclerotic
cardiovascular diseases
BMI  body mass index
HMG-CoA  3-hydroxy-3-
methylglutaryl–coenzyme A
LDL  low-density
lipoprotein
LDLR  low-density
lipoprotein receptor
mRNA  messenger
ribonucleic acid
MTP  microsomal
triglyceride transfer protein
PCSK9  proprotein
convertase subtilisin/kexin
type 9
siRNA  small interfering
ribonucleic acid
SREBP2  sterol-
responsive element-binding
protein 2issue–derived adipokine, in human hepatocyte LDLR expres-sion, examining a previously undescribed relationship between
obese adipose tissue and impaired hepatic LDL regulation.
Resistin is a member of a class of small cysteine-rich secreted
signaling proteins, collectively termed resistin-like molecules
(17). Resistin expression in adipose-tissue adipocytes and
macrophages is increased in obesity, leading to increased
circulating resistin levels (18,19). There are also strong positive
correlations between plasma resistin levels and increases in
body mass index (BMI) and visceral fat (18–20). Conversely,
in overweight and obese humans, serum resistin levels have
been found to consistently decrease with weight loss attributed
to controlled exercise or hypocaloric diets (21–23). Finally, the
importance of resistin as an ASCVD risk factor in obesity is
highlighted by the fact that serum resistin levels in humans are
predictive of coronary atherosclerosis, independent of the
presence of obesity (24).
Our key finding that resistin, at physiological levels observed
in human obesity (50 ng/ml) substantially reduces human
hepatocyte expression of LDLRs (by 40%) (Fig. 1A), suggests
that elevated resistin is a key pathophysiological link be-
tween obesity and elevated LDL and atherogenesis in
humans. Such resistin-mediated reductions in hepatocyte
LDLRs, which we identified in both HepG2 cells and
primary human hepatocytes isolated from fresh human
livers, would be expected to greatly deteriorate the dyslipi-
demic profile of obese individuals (25).
Cross-talk between adipose tissue and metabolically active
tissues, such as the liver, as described earlier, has been noted
before and has been shown to be mediated by adipocyte-
derived adipokines and cytokines (25). Resistin-mediated im-
pairment of hepatocyte LDLR delineates a new physiological/
molecular pathway linking adipose tissue adipokines and
hepatic metabolism. In this study, our goal was to determine if
human resistin plays a role in regulating the uptake of athero-
genic LDL in human hepatocytes.
Methods
For a supplementary description of the Methods section,
please see the online version of this paper.
Results
Dose-response experiments with human resistin in
human hepatocytes. Cultured human hepatic HepG2
cells (American Type Culture Collection) were maintained
in 1% fetal bovine medium–Dulbecco’s modified Eagle’s
medium and treated with recombinant purified human
resistin (Calbiochem, Nottingham, United Kingdom), con-
firmed via denaturing sodium dodecyl sulfate polyacryl-
amide gel electrophoresis (10%) using a rabbit polyclonal
antibody against human resistin (Santa Cruz Biotechnology,
Santa Cruz, California) for detection. A single 12-kDa band
was observed in our resulting immunoblot, confirming that
our resistin source was indeed purified human resistin.
Cryopreserved platable primary human hepatocytes, me-
tabolism qualified from multiple normal human donors,
1699JACC Vol. 59, No. 19, 2012 Melone et al.
May 8, 2012:1697–705 Resistin Inhibits LDLR Levels Via PCSK9were obtained from CellzDirect/Invitrogen, Inc. (Durham,
North Carolina). The cells were incubated in the manufac-
turer’s incubation media for 16 h before human resistin 50
ng/ml treatment for 24 h.
All of the experiments to follow were performed at least 3
times, and representative results are shown. Beta-actin or
glyceraldehyde-3-phosphate dehydrogenase were used as in-
ternal controls to confirm equal protein loading in our Western
blots.
Dose-response experiments were performed in HepG2
cells with 0, 10, 25, 50, 75, and 100 ng/ml of human resistin
for 24 h. Western blots were then performed on cell lysates
to detect the cellular expression of LDLR protein (Figs. 1A
and 1B). Significant reductions in HepG2 LDLR protein
expression, compared with untreated control cells, were
observed at 25- and 50-ng/ml resistin treatments (p 0.01)
and at 75- and 100-ng/ml resistin treatments (p  0.05)
(Fig. 1B). The significant decline in LDLR protein expres-
sion with resistin treatment of HepG2 cells at 50 ng/ml
(40  2%) was confirmed in primary human hepatocytes
(21  6%) (p  0.05) (Fig. 1A).
Mechanisms by which resistin mediates a reduction in
human hepatocyte LDLR levels. Treatment of HepG2
cells with human resistin (50 ng/ml, 24 h) increased cellular
Figure 1 Examination of the Effect of Human Resistin on Huma
(A) Treatment of HepG2 cells and primary human hepatocytes for 24 h with resist
the cellular expression of low-density lipoprotein receptor (LDLR) protein (compare
HepG2 cells in a dose-responsive manner. p  0.05; p  0.01.sterol-responsive element-binding protein 2 (SREBP2)messenger ribonucleic acid (mRNA) expression by 3-fold
and the mRNA expression of SREBP2 target genes, includ-
ing 3-hydroxy-3-methylglutaryl– coenzyme A (HMG-
CoA) reductase, the LDLR, and proprotein convertase
subtilisin/kexin type 9 (PCSK9) (p  0.05 for all versus
untreated control cells) (Fig. 2A). Stimulation of HMG-
CoA reductase by resistin would be expected to increase
cellular de novo lipogenesis, and, indeed, there was an
increase in intracellular neutral lipid content, as assessed
via hematoxylin/Oil Red O staining of hepatocytes (Fig. 2B).
Gas chromatography analysis of lipids extracted from
resistin-treated hepatocytes showed significant increases in
cellular triglyceride (p  0.01) and cholesteryl ester (p 
0.05) contents by 24  1% and 18  4%, respectively
(Fig. 2C).
Hepatocyte PCSK9 protein levels were assessed in re-
sponse to resistin (50 ng/ml, 24 h) treatment. In HepG2
cells, resistin caused a 40  2% increase in PCSK9
expression, and in primary human hepatocytes, resistin
caused a 30  5% increase in PCSK9 protein expression
(p  0.01 for both) (Fig. 2D).
Because PCSK9 is known to induce intracellular degra-
dation of the LDLR (13,14), our goal was to determine if
the resistin-mediated decline in hepatocyte LDLR protein
patocyte LDLR Protein Levels
the level characteristic of obese human serum (50 ng/ml), markedly inhibited
untreated control cells). (B) Resistin reduced cellular LDLR protein levels inn He
in, at
d withlevels involved PCSK9. PCSK9 small interfering ribonu-
c
c
f
L
h
i
h
m
a
s
s
r
L
r
L
1700 Melone et al. JACC Vol. 59, No. 19, 2012
Resistin Inhibits LDLR Levels Via PCSK9 May 8, 2012:1697–705cleic acid (siRNA) treatment of HepG2 cells for 24 h
inhibited PCSK9 mRNA levels significantly by 60  2%
(p  0.01) compared with vehicle control hepatocytes
incubated with transfection reagent alone. Treatment with
small interfering PCSK9 caused a large elevation (114 
15%) in hepatocyte LDLR expression versus untreated
control cells, which was ablated with resistin treatment
(50 ng/ml) (Fig. 3A). Further determination of cellular
PCSK9 protein levels in response to PCSK9 siRNA
Figure 2
Mechanisms Accounting for Reduced Hepatocyte
LDLR Protein Expression by Resistin Treatment
(50 ng/ml, 24 h) of Human Hepatocytes
(A) Resistin significantly increased messenger ribonucleic acid (mRNA) lev-
els of sterol-responsive element-binding protein 2 (SREBP2) and its target
genes in HepG2 cells (versus untreated control cells). (B) HepG2 cells
treated with resistin showed greater accumulation of neutral lipids versus
untreated control cells. (C) HepG2 cells after treatment with human resistin
showed significant increases in cellular neutral lipids. (D) Resistin markedly
increased cellular proprotein convertase subtilisin/kexin type 9 (PCSK9)
protein levels in HepG2 cells and in primary human hepatocytes. LDLR 
low-density lipoprotein receptor; HMG-CoA  3-hydroxy-3-methylglutaryl–
coenzyme A.treatment displayed a 49  1% decline in PCSK9 protein i(p  0.01), an effect that was minimized by the addition
of resistin (50 ng/ml) to a 31  4% decline in PCSK9
protein levels (Fig. 3B).
Quantification of the role of PCSK9 in the resistin-
induced reduction in hepatocyte LDLR levels. Hepato-
cytes were isolated ex vivo from wild-type and PCSK9
gene-deleted mice, treated with resistin (50 ng/ml, 24 h),
and then assessed for LDLR and PCSK9 protein levels by
Western blot. In hepatocytes from wild-type mice, resistin
markedly decreased LDLR protein levels by 37  6%
compared with untreated hepatocytes (p  0.01) and also
increased PCSK9 protein levels by 52  8% (p  0.01)
(Figs. 3C and 3D); however, in PCSK9 knockout mice,
resistin only decreased LDLR levels by 16  1% (p  0.01)
(Fig. 3C).
Effect of resistin on hepatocyte LDLR levels in the
presence of a microsomal triglyceride transfer protein
inhibitor. Microsomal triglyceride transfer protein (MTP)
inhibitors, as a class, reduce the egress of cellular lipids,
thereby causing cellular accumulation of lipids (26). This
action should prevent the stimulation of SREBP by resistin
and determine whether the resistin-mediated reduction in
LDLR protein levels are dependent on SREBP2 stimula-
tion of LDLR expression. MTP inhibition (via CP-346086
at a nontoxic dose that did not reduce cell viability [1.3
nmol/l]) did induce a significant reduction in SREBP2
mRNA expression and its target gene, HMG-CoA reduc-
tase (p  0.05 for both) (Fig. 4A). This reduction in
SREBP2 by CP-346086 reversed the increase in PCSK9
(Fig. 4B) and the decline in LDLR protein levels observed
with resistin treatment (Fig. 4C).
Effect of resistin on hepatocyte LDLR levels in a physio-
logically relevant human setting. HepG2 cells were incu-
bated with serum (10% in Dulbecco’s modified Eagle’s
medium for 24 h) from healthy obese males (BMI 30
kg/m2 and 35 kg/m2 and waist circumference 102 cm)
(n  13) with high resistin concentrations (62% elevated
ompared with lean subjects) (p  0.01) (Fig. 5A) and
ompared them with HepG2 cells incubated with serum
rom lean males (BMI 25 kg/m2 and waist circumference
102 cm) (n  10). The results demonstrated a significant
31  5% inhibitory effect of obese human serum on cellular
DLR protein expression versus lean serum incubation of
epatocytes (p  0.01) (Fig. 5B), and a 39  11% elevation
n PCSK9 levels with obese versus lean serum incubation of
epatocytes (p  0.01) (Fig. 5C).
We then performed antibody-immunoprecipitation re-
oval of resistin from human serum using a polyclonal
ntibody directed against human resistin, and examined the
ubsequent effect on hepatocyte LDLR and PCSK9 expres-
ion. Antibody removal of resistin in obese human serum
eversed the obese serum-mediated reduction in cellular
DLRs by 76  14% (p  0.01) (Fig. 5D). Removal of
esistin in lean human serum also increased hepatocyte
DLR levels by 54  11% (p  0.01) versus lean serumncubation of hepatocytes. Antibody removal of resistin in
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May 8, 2012:1697–705 Resistin Inhibits LDLR Levels Via PCSK9obese human serum reduced PCSK9 expression by 48 
6%, and in lean human serum, it reduced it by 38  5%
p  0.01 for both) (Fig. 5E).
ffect of resistin on statin-mediated up-regulation of
epatocyte LDLR levels. We tested whether resistin
nhibits the normal statin-mediated up-regulation of
epatocyte LDLR levels. Resistin (50 ng/ml, 24 h)
iminished the increase in hepatocyte LDLR expression
nduced by lovastatin treatment (5 M, 24 h) by 60%
p  0.01) (Fig. 6A) and increased cellular PCSK9
rotein by 55% versus lovastatin treatment alone (p 
.01) (Fig. 6B).
iscussion
ultiple studies have consistently shown a strong indepen-
ent relationship between serum resistin levels and LDL
oncentrations in obese humans, demonstrating the rele-
ance of studying resistin–LDL interactions in a human
ontext (27,28). We further found for the first time that
Figure 3 Determination of the Contribution of PCSK9 in the Re
in Hepatocyte LDLR Protein Expression
(A) Resistin reversed the up-regulation of LDLR protein expression in HepG2 cells
siRNA treatment caused a reduction in human hepatocyte PCSK9 protein levels w
together with PCSK9 siRNA. (C) When hepatocytes isolated from wild-type mice w
isolated from PCSK9 knockout mice were treated similarly with resistin, a lesser r
observed when wild-type hepatocytes were treated with resistin. GAPDH  glycerauman resistin treatment of human hepatocytes directly causes dose-response reductions in hepatocyte LDLR pro-
ein levels. The maximum LDLR reduction (of 40%) was
eached at concentrations of resistin characteristic of obese
ndividuals (50 and 75 ng/ml) (19).
We then sought to determine the mechanisms by
hich resistin inhibits hepatocyte LDLR protein expres-
ion. Essentially, a dual control system of hepatic LDLR
xpression is currently recognized (13,14). On the syn-
hesis end, the transcription factor, SREBP2, stimulates
DLR mRNA expression, usually when hepatocytes are
epleted of cholesterol (13,14). The recently identified
ecreted hepatocyte protein of high current interest,
CSK9, then mediates post-transcriptional LDLR protein
egradation (13,14,29,30). PCSK9 binds to the extracellular
omain of the LDLR on the cell surface and then targets
he LDLR, after endocytosis, for intracellular lysosome-
ediated degradation instead of recycling to the plasma
embrane (13,14).
We found that resistin treatment of HepG2 cells in-
-Mediated (50 ng/ml, 24 h) Reduction
d by PCSK9 small interfering ribonucleic acid (siRNA) treatment. (B) PCSK9
ded to hepatocytes alone and a lesser reduction when resistin was added
ated with resistin, a reduction in LDLR levels was observed. When hepatocytes
on in LDLR levels occurred. (D) An increase in cellular PCSK9 protein levels were
e-3-phosphate dehydrogenase; other abbreviations as in Figure 2.sistin
induce
hen ad
ere tre
educti
ldehydreases cellular mRNA expression of SREBP2 and
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Resistin Inhibits LDLR Levels Via PCSK9 May 8, 2012:1697–705SREBP2 target genes, including HMG-CoA reductase, the
rate-limiting protein in intracellular cholesterol biosynthe-
sis. The result of this increase in de novo cellular lipid
biosynthesis mediated by resistin was an increase in intra-
cellular neutral lipid content, particularly a 25% increase in
hepatocyte triglycerides and a 20% increase in cholesteryl
esters. Resistin also stimulated the mRNA expression of
PCSK9, also an SREBP2 target gene (29), which was
reflected in resistin-mediated significant increases in hepa-
tocyte PCSK9 protein levels.
We further investigated the extent of the role of PCSK9
Figure 4 Hepatocyte LDLR and PCSK9 Protein Expression by R
of HepG2 Cells in the Presence of an MTP inhibitor, C
(A) Treatment of HepG2 cells with a microsomal triglyceride transfer protein (MTP
cholesterol synthesis, mediated by a reduction in SREBP2 mRNA expression and i
ing in cellular cholesterol biosynthesis. (B) The addition of CP-346086 to hepatoc
resistin and, moreover, caused a significant decrease in PCSK9 protein compared
reversed the decline in LDLR protein levels observed with resistin treatment. Othein the resistin-mediated reduction in hepatocyte LDLRlevels. We therefore inhibited PCSK9 gene expression in
hepatocytes via PCSK9 siRNA treatment for 24 h. The
addition of resistin reversed the marked more than 100%
elevation in hepatocyte LDLR expression induced with
PCSK9 siRNA treatment and also enhanced cellular
PCSK9 protein levels, compared with siRNA treatment
alone. This finding suggests that resistin stabilizes hepato-
cyte PCSK9 protein. Overall, these findings indicate that
the reduction in cellular LDLR protein levels by resistin
and enhanced LDLR degradation occur, at least in part,
via up-regulation of PCSK9. This is a novel function of
in Treatment (50 ng/ml, 24 h)
6086
itor, CP-346086 (1.3 nmol/l), induced a significant reduction in cellular de novo
et gene, 3-hydroxy-3-methylglutaryl–coenzyme A (HMG-CoA) reductase, rate-limit-
eated with resistin reversed the increase in PCSK9 protein levels induced by
ntreated control cells. (C) Treatment of human hepatocytes with CP-346086
viations as in Figures 2 and 3.esist
P-34
) inhib
ts targ
ytes tr
with u
r abbrehuman resistin and is the first identification of a natural
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May 8, 2012:1697–705 Resistin Inhibits LDLR Levels Via PCSK9serum factor directly regulating PCSK9 protein levels in
hepatocytes.
To more directly quantify the role of PCSK9 in the
resistin-mediated reduction in hepatocyte LDLR levels,
hepatocytes isolated and cultured from wild-type mice were
treated with resistin, and we then compared them with
resistin-treated hepatocytes from PCSK9 knockout mice. In
wild-type mice hepatocytes, resistin markedly decreased
LDLR protein levels by 40%, compared with untreated
hepatocytes, and also increased PCSK9 levels significantly,
similar to our findings in human hepatocytes. Resistin also
significantly decreased LDLR expression in hepatocytes
from PCSK9 knockout mice, but the magnitude of the
effect was reduced to a 15% decline in LDLR expression
compared with untreated hepatocytes from PCSK9 knock-
out mice. These findings show that the elevation in PCSK9
Figure 5 The Role of Resistin on Human Hepatocyte LDLR and
(A) Serum resistin levels were elevated in obese human serum (n  13) compare
fied Eagle’s medium [DMEM], 24 h), with elevated resistin levels, had a significan
with lean human serum (10% in DMEM, 24 h). (C) Obese human serum caused a
(D) Antibody-immunoprecipitation removal of resistin from obese serum caused a
lean serum. (E) The amelioration of hepatocyte LDLR levels with antibody-immuno
least in part, to reduction in hepatocyte PCSK9 protein expression. Abbreviationsprotein levels induced by resistin plays a major, but notexclusive, role in the reduction of cellular LDLR levels
mediated by resistin.
We next used inhibitors of MTP (26) to determine if excess
accumulation of intracellular lipids through MTP inhibition
would ameliorate the cellular up-regulation of SREBP2 and its
targets, particularly PCSK9, induced by resistin, thereby ame-
liorating the effects of resistin. MTP inhibition, via CP-
346086, induced a significant reduction in cellular SREBP2
mRNA expression, and it thereby reversed the increase in
PCSK9 protein levels induced by resistin and thus reversed the
decline in LDLR protein levels observed with resistin. These
results indicate that the SREBP2-mediated elevation in hepa-
tocyte PCSK9 levels contributes to the decline in cellular
LDLR levels induced by resistin.
We wished to further determine if, in a physiologically
relevant human setting, resistin inhibits hepatocyte LDLR
9 in a Physiologically Relevant Human Setting
lean human serum (n  10). (B) Obese human serum (10% in Dulbecco’s modi-
itory effect on HepG2 LDLR expression compared with hepatocytes incubated
r induction in hepatocyte PCSK9 expression compared with lean human serum.
r increase in HepG2 LDLR expression compared with removal of resistin from
itation removal of resistin from both obese and lean serum was attributed, at
igures 2 and 3.PCSK
d with
t inhib
greate
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as in Fprotein expression. We therefore incubated human hepatocytes

r
s
s
i
e
c
m
s
b
o
m
r
l
a
h
m
t
p
i
p
f
t
v
P
s
m
a
e
a
s
R
e
1704 Melone et al. JACC Vol. 59, No. 19, 2012
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35 kg/m2 and waist circumference 102 cm) with high
esistin concentrations (60% elevated compared with lean
ubjects) and compared them with hepatocytes incubated with
erum from lean males (BMI 25 kg/m2 and waist circum-
ference 102 cm). The results demonstrated a greater inhib-
tory effect of obese human serum on cellular LDLR protein
xpression than lean serum incubation of hepatocytes, con-
omitant with a greater elevation in PCSK9 levels.
We then performed antibody-immunoprecipitation re-
oval of resistin from human serum and examined the
ubsequent effect on hepatocyte LDLR expression. Anti-
ody removal of resistin in obese human serum reversed the
bese serum–mediated reduction in cellular LDLRs re-
arkably (by 80%), an effect that was mediated in part by
educed PCSK9 expression (by 50%). Removal of resistin in
ean human serum also increased hepatocyte LDLR levels,
lbeit to a lesser extent. These results indicate that resistin in
uman serum plays a quantitatively important role in
ediating hepatocyte LDLR levels. This further indicates
hat reduction or inhibition of serum resistin in humans is a
otentially effective treatment for elevated LDL, particularly
n obese states.
The major class of drugs currently administered to
atients with elevated serum LDL are statins. Statins
unction by reducing cellular cholesterol levels; this reduc-
ion activates SREBP2, leading to the transcriptional acti-
Figure 6 The Effect of Resistin (50 ng/ml, 24 h) on
Statin-Mediated LDLR Regulation in HepG2 Cells
(A) Lovastatin treatment of HepG2 cells (5 M, 24 h) significantly increased
cellular LDLR levels, as expected. The addition of resistin to lovastatin greatly
diminished the statin-mediated up-regulation of cellular LDLR levels. (B) The
addition of resistin to lovastatin increased cellular PCSK9 levels. Abbreviations
as in Figures 2 and 3.ation of the LDLR (13). Because resistin stimulatesCSK9, the resistin-mediated increase in PCSK9 expres-
ion, which should be more prevalent in obese individuals,
ay attenuate the increase in LDLR expression in patients
dministered statins. Consistent with this concept, the
vidence suggests that obese individuals are less likely to
chieve optimal LDL lowering with statin therapy (31–34).
We therefore tested whether resistin inhibits the normal
tatin-mediated up-regulation of hepatocyte LDLR levels.
esistin diminished the increase in hepatocyte LDLR
xpression induced by lovastatin treatment (5 M) consid-
erably (by 60%). This inhibition of the statin-induced
LDLR up-regulation by resistin was attributed in part to
increased cellular PCSK9 protein levels (by 55%). These
results indicate that inhibitors of resistin may act synergis-
tically with statins to enhance hepatocyte LDLR expression
and reduce plasma LDL levels.
In general, there is considerable controversy on the role of
resistin in the metabolic complications of obesity. Although
correlations between serum resistin and LDL levels in
humans have been shown in multiple reports (27,28), no
causal role of resistin in LDL regulation has previously been
shown in humans. Here we have demonstrated that human
resistin robustly inhibits human hepatocyte LDLR protein
expression. We have further identified that PCSK9-
mediated enhanced LDLR degradation is a major, but not
exclusive, mechanism by which resistin exerts its inhibitory
effect on cellular LDLR levels. We have also shown a direct
effect of resistin on LDLRs, independent of PCSK9, in
our experiments with resistin treatment of hepatocytes
isolated from PCSK9 knockout mice. Analysis of the crystal
structure of PCSK9 has showed, intriguingly, that PCSK9
and resistin share a fully folded C-terminal cysteine-rich
domain (35). It has thus been suggested that resistin and
PCSK9 compete for or share a common receptor, likely the
LDLR, which will need to be discerned in future studies in
in vitro and in vivo settings. In addition to the aforemen-
tioned mechanistic insights, our studies with resistin suggest
that in a clinical setting, elevated resistin in obese humans
may mask the full potential of statins in LDL lowering,
which has important implications on patient segregation
and targeted drug therapy. This will need to be specifically
tested in future clinical studies.
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For an expanded Methods section,
please see the online version of this article.
